Shenwei Pharmaceutical (2877.HK): Rapid growth in performance, smooth progress in research and development of new drugs
CCB International: Maintaining Shenwei Pharmaceutical (02877)'s “Outperforming Market” Rating, Target Price Reduced to HK$9.5
Research Report Nuggets | China Merchants Securities: The target price for the first “increase in holdings” rating for Shenwei Pharmaceutical is HK$13.8
Changes in Hong Kong stocks | Shenwei Pharmaceutical (02877) rose by more than 7% and is expected to increase profits by at least 25% year-on-year last year, Daimo raised its earnings estimates and target prices
Changes in Hong Kong stocks | Shenwei Pharmaceutical rose 2 days in a row after making a profit, raised target prices and tested profit
Big Bank Ratings | Morgan Stanley: Raising the target price of Shenwei Pharmaceutical to HK$7.8 to maintain the same rating as the market
Jefferies: Upgraded the rating of Shenwei Pharmaceutical (02877) to “buy” target price by 59% to HK$14
Shenwei Pharmaceutical (02877.HK): Chinese medicine formulations are growing rapidly, and companies have abundant cash flow
Shenwei Pharmaceutical (2877.HK): Growth is expected to resume in the second quarter
Shenwei Pharmaceutical (2877.HK): Sales are expected to slow in the fourth quarter of '18
SHENWEI PHARMACEUTICAL (2877.HK): Reverse Roadshow Summary; Formulated Particles Are the Main Growth Engine
Shenwei Pharmaceutical (2877.HK): summary of reverse roadshow in Shijiazhuang
Shenwei Pharmaceutical (2877.HK): sustained recovery in the second quarter valuation attracts
Shenwei Pharmaceutical (2877.HK): strong performance in the first quarter confirms the trend of recovery
Shenwei Pharmaceutical (2877.HK): strong recovery momentum
Shenwei Pharmaceutical (2877.HK): performance is back on track
Shenwei Pharmaceutical (2877.HK): reappearance of Dawn
Shenwei Pharmaceutical (2877.HK) Quarterly Report Review: Third-quarter results are still weak and maintain a “sell” rating
Deutsche Bank downgraded the rating of Shenwei Pharmaceutical (02877.HK) from holding to selling, reducing the target price to 6.5 yuan
Shenwei Pharmaceutical (2877.HK): Announces acquisition of Beijing Wantel Biopharmaceutical Co., Ltd.; maintains neutral rating and lowers target price to HK$9.96
No Data